PT-141 (Bremelanotide): What research reveals about its effects

PT-141, also known as Bremelanotide, is a research peptide that has shown promise in scientific studies, on animal test subjects, to regulate blood flow restriction, inflammation, and helping improve sexual dysfunction. PT-141 was developed from the Melanotan 2 Peptide, which underwent studies in a laboratory setting as a sunless tanning agent. It is from this scientific testing that the potential benefits of PT-141 were discovered. Scientists have determined through rigorous testing on animal test subjects, because of the ability to regulate blood flow restriction and inflammation by PT-141, it very well may be instrumental in managing the onset of hemorrhagic shock and reperfusion injury. What this means is it could potentially reduce, or outright prevent inflammation that may be triggered by a variety of irritants or diseases. This, in turn, could also help reduce any damage that could potentially occur within blood vessels and surrounding tissue. Additional studies have determined PT-141 is a potential remedy for the treatment of sexual dysfunction. Results from early research studies have shown PT-141 does not act on the vascular system like former compounds but works by activating the melanocortin receptors in the brain.

Warning
THE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals.

References / Links

1. Shadiack, A. M., et al. (2004). Melanocortins in the treatment of male and female sexual dysfunction. Peptides, 25(3), 525–528. PubMed
2. Diamond, L. E., et al. (2004). Bremelanotide for the treatment of female sexual dysfunction: results of two randomized, double-blind, placebo-controlled, dose-ranging studies. Journal of Sexual Medicine, 1(2), 145–153. PubMed
3. Kingsberg, S. A., et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women: two randomized phase 3 trials. Obstetrics & Gynecology, 134(5), 899–908. PubMed
4. US Food and Drug Administration (2019). Bremelanotide approval (Vyleesi, injection). FDA